Holen Sie sich die Stockscreener-App
12.71
3.58%
0.435
Schlusskurs vom Vortag:
$12.28
Offen:
$12.38
24-Stunden-Volumen:
414.27K
Relative Volume:
0.33
Marktkapitalisierung:
$839.14M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-8.0475
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-1.55%
1M Leistung:
+12.67%
6M Leistung:
+81.84%
1J Leistung:
+192.41%
1-Tages-Spanne:
$12.23
$12.85
1-Wochen-Bereich:
$11.98
$13.00
52-Wochen-Spanne:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
12.72 | 810.12M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.50 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.30 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.44 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
853.84 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.75 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Insider Monkey
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38 - Nasdaq
How Fulcrum Therapeutics Inc. stock performs in stagflationWeekly Trade Summary & Low Volatility Stock Suggestions - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc stock is a must watch in 20252025 Investor Takeaways & High Yield Stock Recommendations - moha.gov.vn
What makes Fulcrum Therapeutics Inc. stock attractive to growth fundsJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Why Fulcrum Therapeutics Inc. stock is considered a top pick2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Is Fulcrum Therapeutics Inc. stock undervalued vs historical averages2025 Performance Recap & Community Driven Trade Alerts - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc. stock is a must watch in 2025 - ulpravda.ru
Is Fulcrum Therapeutics Inc. stock supported by strong cash flows - ulpravda.ru
Published on: 2025-12-19 18:03:13 - DonanımHaber
Can Fulcrum Therapeutics Inc. stock deliver consistent earnings growthQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
Why Fulcrum Therapeutics Inc. stock is a must watch in 20252025 Dividend Review & Low Risk Investment Opportunities - Улправда
Can Fulcrum Therapeutics Inc. stock surprise with earnings upsideTrade Signal Summary & Technical Confirmation Trade Alerts - DonanımHaber
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterJuly 2025 Sector Moves & Real-Time Volume Triggers - DonanımHaber
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Trends: Will Fulcrum Therapeutics Inc. stock attract more institutional investorsWeekly Investment Report & Technical Entry and Exit Tips - Улправда
Insider Sell: Curtis Oltmans Sells Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% on Insider Selling - Defense World
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - ca.investing.com
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Owner RA Capital Management LP Sells 4,175,139 ($58.4M) Of Fulcrum Therapeutics Inc [FULC] - TradingView — Track All Markets
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics stock falls after pricing $175 million public offering By Investing.com - Investing.com Canada
Fulcrum Therapeutics prices $175 million public offering By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Prices $175 Million Stock Offering - marketscreener.com
Fulcrum Therapeutics prices $175 million public offering - Investing.com
What is HC Wainwright's Forecast for FULC FY2028 Earnings? - MarketBeat
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Fulcrum Therapeutics announces pricing of upsized $175.0 million public offering of common stock and pre-funded warrants - marketscreener.com
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation - Nasdaq
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.8% on Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView — Track All Markets
Owner RA Capital Healthcare Fund LP Files To Sell 4,175,139 Of Fulcrum Therapeutics Inc [FULC] - TradingView — Track All Markets
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):